Receptor.AI and Ono Join Forces to Advance AI-Powered Drug Discovery

Receptor.AI, a leading preclinical TechBio company transforming drug discovery through AI, has announced a new research collaboration with Ono Pharmaceutical Co., Ltd. ("Ono") aimed at designing novel drug candidates. Through this partnership, both companies will jointly pursue the identification and development of therapeutic compounds with improved potency, selectivity, and pharmacological characteristics.

"Our collaboration with Ono underscores our commitment to employing advanced AI-driven methods in drug discovery," said Dr. Alan Nafiiev, CEO of Receptor.AI. "By combining Ono's long-standing legacy in discovering innovative therapies with Receptor.AI's multiplatform ecosystem, we aim to accelerate the path from concept to clinic—ultimately bringing transformative treatments to patients who need them most."

"We have high regard for Receptor.AI's generative AI technology and computational platforms," said Seishi Katsumata, Corporate Officer / Executive Director, Discovery & Research of Ono. "Receptor.AI's proven track record in streamlining early-stage discovery aligns with our pursuit of breakthrough therapies. We look forward to making significant progress together and advancing our shared R&D efforts."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.